Lancet:PEEP结合肺复张法不能预防开腹手术术后肺并发症

2014-10-08 leiqc 丁香园

目前关于术中全身麻醉期间采用机械通气中呼气末正压通气的作用仍不确定。 高于0 cm H2O 的压力水平或许能防止术后肺部并发症,但也可能导致术中循环抑制和过度膨胀造成的肺损伤。 因此,来自新西兰阿姆斯特丹大学重症监护医学与学术医学中心的Hemmes SN教授带领团队对开腹外科手术全身麻醉期间接受低换气量机械通气的有并发症风险患者采用高呼气末正压通气结合肺复张方法,探讨该方法是否可以防止术后肺部并

目前关于术中全身麻醉期间采用机械通气中呼气末正压通气的作用仍不确定。 高于0 cm H2O 的压力水平或许能防止术后肺部并发症,但也可能导致术中循环抑制和过度膨胀造成的肺损伤

因此,来自新西兰阿姆斯特丹大学重症监护医学与学术医学中心的Hemmes SN教授带领团队对开腹外科手术全身麻醉期间接受低换气量机械通气的有并发症风险患者采用高呼气末正压通气结合肺复张方法,探讨该方法是否可以防止术后肺部并发症的发生。

该研究是一项涉及欧洲、北美和南美30个中心的随机对照研究,共有900例全身麻醉和在 8 mL/kg 换气量通气条件下接受开腹手术且有术后肺部并发症风险的患者。研究者将患者随机分配至高呼气末正压 (12cm H2O) 结合肺复张组(高 PEEP 组)或低呼气末正压 (≤2 cm H2O) 不结合肺复张组(低 PEEP 组)。

研究者使用集中式计算机随机分配系统。患者和转归评估者均对干预措施不知情。主要观察指标是术后第 5 天的术后肺部并发症。采用意向治疗人群进行分析。

从 2011 年 2 月到2013 年 1 月,447 例患者被随机分配到高 PEEP 组,453 例被随机分配到低 PEEP 组。有 6 例患者被排除在分析之外,其中 4 例是因其撤销同意书,另2 例是因其违反了纳入标准。

002.jpg

研究结果显示,呼气末正压通气的压力中位数分别为:高PEEP组12cm H2O,低 PEEP 组 2 cm H2O。 术后肺部并发症的人数为:高 PEEP 组的 445 例患者中有 174 例 (40%),相比之下,低 PEEP 组的 449 例患者中有 172 例 (39%)。与低 PEEP 组的患者相比,高 PEEP 组的患者出现了术中低血压,并且需要更大用量的血管活性药物。

上述研究结果表明,开腹手术期间采用高呼气末正压通气结合肺复张之法并不能防止术后肺并发症。术中保护性通气策略应该包括低换气量,低呼气末正压通气,且不宜采用肺复张之法。

原始出处

PROVE Network Investigators for the Clinical Trial Network of the European Society of Anaesthesiology, Hemmes SN, Gama de Abreu M, Pelosi P, Schultz MJ.High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial.Lancet. 2014 Aug 9


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=48042, encodeId=e1614804284, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:39:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757635, encodeId=41411e57635f0, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 07 11:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725662, encodeId=2dac1e2566257, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 12 01:12:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827884, encodeId=dbda182e8844b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 20 03:12:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649754, encodeId=35671649e54d3, content=<a href='/topic/show?id=4a3113996b7' target=_blank style='color:#2F92EE;'>#PEEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13996, encryptionId=4a3113996b7, topicName=PEEP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=459f23920817, createdName=lsndxfj, createdTime=Thu Oct 09 05:12:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506810, encodeId=98cc15068104b, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Fri Oct 10 00:12:00 CST 2014, time=2014-10-10, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=48042, encodeId=e1614804284, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:39:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757635, encodeId=41411e57635f0, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 07 11:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725662, encodeId=2dac1e2566257, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 12 01:12:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827884, encodeId=dbda182e8844b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 20 03:12:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649754, encodeId=35671649e54d3, content=<a href='/topic/show?id=4a3113996b7' target=_blank style='color:#2F92EE;'>#PEEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13996, encryptionId=4a3113996b7, topicName=PEEP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=459f23920817, createdName=lsndxfj, createdTime=Thu Oct 09 05:12:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506810, encodeId=98cc15068104b, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Fri Oct 10 00:12:00 CST 2014, time=2014-10-10, status=1, ipAttribution=)]
    2015-07-07 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=48042, encodeId=e1614804284, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:39:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757635, encodeId=41411e57635f0, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 07 11:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725662, encodeId=2dac1e2566257, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 12 01:12:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827884, encodeId=dbda182e8844b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 20 03:12:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649754, encodeId=35671649e54d3, content=<a href='/topic/show?id=4a3113996b7' target=_blank style='color:#2F92EE;'>#PEEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13996, encryptionId=4a3113996b7, topicName=PEEP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=459f23920817, createdName=lsndxfj, createdTime=Thu Oct 09 05:12:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506810, encodeId=98cc15068104b, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Fri Oct 10 00:12:00 CST 2014, time=2014-10-10, status=1, ipAttribution=)]
    2015-05-12 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=48042, encodeId=e1614804284, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:39:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757635, encodeId=41411e57635f0, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 07 11:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725662, encodeId=2dac1e2566257, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 12 01:12:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827884, encodeId=dbda182e8844b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 20 03:12:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649754, encodeId=35671649e54d3, content=<a href='/topic/show?id=4a3113996b7' target=_blank style='color:#2F92EE;'>#PEEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13996, encryptionId=4a3113996b7, topicName=PEEP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=459f23920817, createdName=lsndxfj, createdTime=Thu Oct 09 05:12:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506810, encodeId=98cc15068104b, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Fri Oct 10 00:12:00 CST 2014, time=2014-10-10, status=1, ipAttribution=)]
    2015-08-20 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=48042, encodeId=e1614804284, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:39:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757635, encodeId=41411e57635f0, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 07 11:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725662, encodeId=2dac1e2566257, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 12 01:12:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827884, encodeId=dbda182e8844b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 20 03:12:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649754, encodeId=35671649e54d3, content=<a href='/topic/show?id=4a3113996b7' target=_blank style='color:#2F92EE;'>#PEEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13996, encryptionId=4a3113996b7, topicName=PEEP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=459f23920817, createdName=lsndxfj, createdTime=Thu Oct 09 05:12:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506810, encodeId=98cc15068104b, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Fri Oct 10 00:12:00 CST 2014, time=2014-10-10, status=1, ipAttribution=)]
    2014-10-09 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=48042, encodeId=e1614804284, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:39:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757635, encodeId=41411e57635f0, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 07 11:12:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725662, encodeId=2dac1e2566257, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 12 01:12:00 CST 2015, time=2015-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827884, encodeId=dbda182e8844b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 20 03:12:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649754, encodeId=35671649e54d3, content=<a href='/topic/show?id=4a3113996b7' target=_blank style='color:#2F92EE;'>#PEEP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13996, encryptionId=4a3113996b7, topicName=PEEP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=459f23920817, createdName=lsndxfj, createdTime=Thu Oct 09 05:12:00 CST 2014, time=2014-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506810, encodeId=98cc15068104b, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Fri Oct 10 00:12:00 CST 2014, time=2014-10-10, status=1, ipAttribution=)]

相关资讯

PLoS ONE:靶向肺的药物递送载体成功减轻肺部炎症

对于经历多次输血,肺部手术的人,以及败血症,急性肺创伤患者来说,肺部炎症会引起浅呼吸以及肺部进一步的损伤。迄今为止,还没有药物能成功地预防或减轻肺部炎症引起的肺损伤。 现在,由David Eckmann医学博士领导的一个多学科研究小组发现,利用一个微小转运载体即纳米载体,可以成功递送地塞米松到达肺血管的内皮细胞,并且新的递送系统能成功地预防小鼠肺部炎症。相关研究发表在PLOS One杂志上。 在

NEJM:新生儿高频率振荡通气远期疗效好

极低胎龄儿通常需要进行机械通气,高频振荡通气(HFOV)是一种可减少支气管-肺发育不良风险的治疗手段,通过施加恒定的气道压力改善肺容积与氧合。有报道早产儿常规机械通气会导致小气道功能下降,但研究并未发现初始给予HFOV支持的婴儿会出现小气道功能的明显下降。 尽管荟萃分析结果表明,HFOV可减少支气管-肺发育不良的风险,但目前关于接受HFOV婴幼儿肺功能的随访数据有限。为确定HFOV的长期疗效,研

A&R:甲氨蝶呤可增加RA患者肺部疾病的发生

甲氨蝶呤对很多疾病有治疗效果,尤其是类风湿关节炎。既往的研究提示甲氨蝶呤有可能会引起间质性肺疾病,并且增加呼吸系统感染的风险。为了明确甲氨蝶呤治疗RA患者罹患肺部疾病的危险度,来自爱尔兰国立高威大学医院的Richard Conway 等研究者对既往的相关研究结果进行了Meta分析,结果发表在2014年Arthritis & Rheumatism杂志上。 这项分析纳入的数据来自Pubmed

Chest:药物治疗肺动脉高压疗效和安全性比较

目前,用于肺动脉高压(PAH)治疗的药物主要有三类,即内皮素受体拮抗剂、磷酸二酯酶-5抑制剂和前列腺素。这些药都显示具有改善患者呼吸困难、6分钟步行距离(6MWD)和肺血液动力学的作用。然而很少有关于不同药物联合治疗的有效性和安全性比较,或药物治疗对死亡率影响的研究。 来自美国北卡罗莱纳州杜克大学医学院的Coeytaux教授等进行的一项系统评价和Mata分析显示,单药及药物联合治疗可使肺动脉高压

Expert Rev Respir Med:间质性肺疾病使用免疫抑制剂相关技巧

免疫抑制在间质性肺疾病(ILD)治疗中有重要作用,其对某些ILD,如特发性肺纤维化(IPF)无效,对另一些则效果较好。同时,其可能带来的风险也很大,如:感染,糖尿病,骨质疏松,肌病,骨髓抑制,肝炎,泌尿道损伤,药物性肺炎等。本文将阐述在ILD中是否应使用免疫抑制治疗,怎样使用,怎样监测,以及怎样减少可能的副作用等。 使用免疫抑制剂治疗ILD的证据 在ILD中,常用的免疫抑制是激素和细胞毒性药物

PNAS:肺纤维囊肿为何对感染敏感

“我们发现呼吸道通过分泌表面液体对吸入的细菌有反应”生理学助理教授Juan Ianowski 说“这是一个未知的先天性免疫防御固有组成部分”这一发现表明通过帮助这个组成部分更好地发挥功能——例如,通过早期和持续使用抗生素有可能提高囊性纤维化患者的肺功能。 呼吸道表面液体(ASL)是“黏液纤毛清除功能”系统的一部分。ASL包括粘液层细菌,灰尘及其它粒子和薄液层,粘液“漂浮”